Crinetics Pharmaceuticals (CRNX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Key Insights
Critical company metrics and information
Share Price
$58.07Market Cap
$5.39 BillionTotal Outstanding Shares
92.74 Million SharesTotal Employees
210Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.crinetics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $174.47 Million |
Net Cash Flow From Operating Activities, Continuing | $-199.81 Million |
Net Cash Flow | $174.47 Million |
Net Cash Flow From Operating Activities | $-199.81 Million |
Net Cash Flow From Financing Activities | $494.32 Million |
Net Cash Flow From Investing Activities, Continuing | $-120.04 Million |
Net Cash Flow From Financing Activities, Continuing | $494.32 Million |
Net Cash Flow From Investing Activities | $-120.04 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $3.70 |
Nonoperating Income/Loss | $33.53 Million |
Income/Loss From Continuing Operations Before Tax | $-294.33 Million |
Benefits Costs and Expenses | $218.54 Million |
Revenues | $1.04 Million |
Costs And Expenses | $299.73 Million |
Diluted Average Shares | $158.85 Million |
Other Operating Expenses | $87.15 Million |
Basic Average Shares | $158.85 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Earnings Per Share | $3.70 |
Research and Development | $219.17 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations After Tax | $-277.91 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-277.91 Million |
Depreciation and Amortization | $2.26 Million |
Operating Expenses | $307.81 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Operating Income/Loss | $-306.77 Million |
Net Income/Loss | $-277.91 Million |
Net Income/Loss Attributable To Parent | $-277.91 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $14.89 Million |
Equity | $832.98 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Liabilities | $50.83 Million |
Other Current Liabilities | $48.62 Million |
Other Non-current Assets | $48.08 Million |
Cash | $862.70 Million |
Noncurrent Assets | $59.79 Million |
Equity Attributable To Parent | $832.98 Million |
Liabilities | $104.39 Million |
Current Liabilities | $53.56 Million |
Current Assets | $877.59 Million |
Fixed Assets | $11.71 Million |
Liabilities And Equity | $937.37 Million |
Assets | $937.37 Million |
Accounts Payable | $4.94 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.